This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Ablynx N.v.. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021
Title: Mark Edward Labadia: Innovator in Immunoglobulin Research
Introduction
Mark Edward Labadia is a notable inventor based in Ridgefield, CT (US). He has made significant contributions to the field of immunology, particularly through his innovative work on immunoglobulins.
Latest Patents
Labadia holds a patent for KV1.3 binding immunoglobulins. This invention relates to immunoglobulins that specifically bind to Kv1.3, including polypeptides and nucleic acids encoding such polypeptides. The patent also covers methods for preparing these polypeptides and compositions, especially pharmaceutical compositions that utilize these polypeptides for prophylactic, therapeutic, or diagnostic purposes. Notably, the immunoglobulins developed by Labadia inhibit the activity of Kv1.3.
Career Highlights
Mark Edward Labadia is associated with Ablynx N.V., where he continues to advance his research in immunoglobulin technology. His work has the potential to impact various therapeutic areas, showcasing his commitment to innovation in the medical field.
Collaborations
Labadia collaborates with esteemed colleagues, including Diane Van Hoorick and Erik Depla, who contribute to his research endeavors.
Conclusion
Mark Edward Labadia's contributions to immunoglobulin research exemplify the spirit of innovation in the scientific community. His patent on KV1.3 binding immunoglobulins highlights the importance of his work in developing new therapeutic solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile